ArticleBMC pediatrics2025
Elevated serum cobalamin levels in childhood: a retrospective analysis.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vitamin B12 in early childhood: a phenotype-guided approach to deficiency and unexpectedly elevated concentrations.European journal of pediatrics · 2026Review
- Hypercobalaminemia in children: clinical characteristics and ınherited metabolic diagnoses in a tertiary-center cohort.European journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCobalamin (Cbl) is a water-soluble vitamin. While its deficiency is well recognized, the clinical significance of elevated serum Cbl levels remains unclear, particularly in children. This study aimed to investigate the clinical and laboratory findings in pediatric patients with excessively high Cbl levels to identify potential underlying causes and outcomes.
methodsIn this retrospective study, pediatric patients with serum Cbl levels > 1500 ng/mL at Ankara Bilkent City Hospital between January and May 2024 were evaluated. Clinical and laboratory data - including demographics, Cbl treatment, chronic disease history, lab results, and imaging - were analyzed.
resultsA total of 388 patients (median age 6, 46.4% male) were included. Cbl treatment was reported in 45.4% of patients, and significantly higher Cbl levels were observed in this group (p < 0.001). Among those with chronic diseases, leukemia and tumors were the most common. Of the children with elevated Cbl levels, 81.3% were asymptomatic. Five patients with no known chronic diseases or history of supplementation at presentation were later diagnosed with rhabdomyosarcoma, AML, B-cell lymphoma, and CML. Ultrasonographic abnormalities, such as steatosis, hepatosplenomegaly, and increased renal echogenicity, were more frequently observed in patients with high Cbl levels (p = 0.013). Patients with chronic diseases exhibited higher Cbl levels and prolonged normalization periods (p < 0.001).
conclusionAlthough high serum Cbl levels in children are often incidental, persistently elevated levels without a clear cause may indicate serious underlying conditions, including malignancies. Close monitoring, further investigation, and avoidance of unnecessary Cbl supplementation are essential for appropriate clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.